- Primary schools empty as smog persists in Indian capital
- Palestinians turn to local soda in boycott of Israel-linked goods
- Typhoon Man-yi bears down on Philippines still reeling from Usagi
- UK growth slows in third quarter, dealing blow to Labour government
- Chris Wood hits quickfire double in NZ World Cup qualifying romp
- Markets struggle at end of tough week
- China tests building Moon base with lunar soil bricks
- Film's 'search for Palestine' takes centre stage at Cairo festival
- Oil execs work COP29 as NGOs slam lobbyist presence
- Gore says climate progress 'won't slow much' because of Trump
- 'Megaquake' warning hits Japan's growth
- Stiff business: Berlin startup will freeze your corpse for monthly fee
- Wars, looming Trump reign set to dominate G20 summit
- Xi, Biden attend Asia-Pacific summit, prepare to meet
- Kyrgios to make competitive return at Brisbane next month after injuries
- Dominican Juan Luis Guerra triumphs at 25th annual Latin Grammys
- Landslide win for Sri Lanka president's leftist coalition in snap polls
- Australian World Cup penalty hero Vine takes mental health break
- As Philippines picks up from Usagi, a fresh storm bears down
- Tropical Storm Sara pounds Honduras with heavy rain
- Pepi gives Pochettino win for USA in Jamaica
- 'Hell to heaven' as China reignite World Cup hopes with late winner
- Rebel attacks keep Indian-run Kashmir on the boil
- New Zealand challenge 'immense but fantastic' for France
- Under pressure England boss Borthwick in Springboks' spotlight
- All Blacks plan to nullify 'freakish' Dupont, says Lienert-Brown
- TikTok makes AI driven ad tool available globally
- Japan growth slows as new PM readies stimulus
- China retail sales pick up speed, beat forecasts in October
- Asian markets fluctuate at end of tough week
- Gay, trans people voicing -- and sometimes screaming -- Trump concerns
- Argentina fall in Paraguay, Brazil held in Venezuela
- N. Korean leader orders 'mass production' of attack drones
- Pakistan's policies hazy as it fights smog
- Nature pays price for war in Israel's north
- New Zealand's prolific Williamson back for England Test series
- Mexico City youth grapple with growing housing crisis
- After Trump's victory, US election falsehoods shift left
- Cracks deepen in Canada's pro-immigration 'consensus'
- Xi inaugurates South America's first Chinese-funded port in Peru
- Tyson slaps Paul in final face-off before Netflix bout
- England wrap-up T20 series win over West Indies
- Stewards intervene to stop Israel, France football fans clash at Paris match
- Special counsel hits pause on Trump documents case
- Japan's Princess Mikasa, great aunt to emperor, dies aged 101
- Cricket at 2028 Olympics could be held outside Los Angeles
- Trump names vaccine skeptic RFK Jr. to head health dept
- Ye claims 'Jews' controlling Kardashian clan: lawsuit
- Japan into BJK Cup quarter-finals as Slovakia stun USA
- Sri Lanka president's party headed for landslide: early results
RBGPF | 100% | 61.84 | $ | |
BCC | -1.57% | 140.35 | $ | |
CMSC | -0.24% | 24.55 | $ | |
BCE | -1.38% | 26.84 | $ | |
RIO | -0.31% | 60.43 | $ | |
SCS | -0.75% | 13.27 | $ | |
JRI | -0.23% | 13.21 | $ | |
NGG | 0.4% | 62.37 | $ | |
GSK | -2.09% | 34.39 | $ | |
RYCEF | -4.71% | 6.79 | $ | |
RELX | -0.37% | 45.95 | $ | |
CMSD | -0.02% | 24.725 | $ | |
AZN | -0.38% | 65.04 | $ | |
BTI | 0.2% | 35.49 | $ | |
VOD | -0.81% | 8.68 | $ | |
BP | 1.65% | 29.05 | $ |
Pfizer Covid pill preventing hospitalizations and deaths: White House
Pfizer's anti-Covid pill Paxlovid is helping stave off hospitalizations and deaths amid the United States' latest wave of infections, a senior White House official said Wednesday.
Demand for the treatment has soared, with a four-fold increase over the past month and an estimated 20,000 prescriptions being written every day, White House Covid-19 Response Coordinator Ashish Jha told reporters in a press call.
"I think that is actually a really important reason why, despite this very substantial increase in infections, we have not seen a commensurate increase in deaths," he said.
"We have seen hospitalizations rise, but again, not as much as one would have expected at this point, despite the fact that hospitalizations do lag. When you look at ICU care, the rate of ICU hospital admissions is much lower than what one would expect."
President Joe Biden's administration last month embarked on an aggressive push to expand access to the oral antiviral at tens of thousands of locations across the country.
Omicron's subvariants have driven daily new cases to 94,000, a three-fold increase over the last month, with hospitalizations running at 3,000 a day, and deaths at around 275.
Paxlovid, a combination of two drugs, both taken orally over five days, was shown in a clinical trial to reduce hospitalizations and deaths among at-risk people by almost 90 percent.
Concerns have been raised about "Paxlovid rebound" -- in which some patients clear the virus while on the treatment, but test positive after completing their course.
Jha said the government was studying the issue closely, "but I think it is not leading to people getting particularly sick." The rate of rebound during Paxlovid's clinical trial was two percent, but the dominant variant at the time was Delta.
He also encouraged doctors to adopt a "relatively permissive" approach to prescribing the medicine, given the broad eligibility criteria for being high risk.
"You should not get excessively restrictive, we have plenty of supply right now," he advised doctors.
Jha also urged Congress to quickly provide $22.5 billion in Covid funding so that the government could ensure the supply of next generation Covid vaccines, which are expected to protect against multiple variants.
"Other countries are in conversations with the manufacturers and starting to advance their negotiations," he said, warning Americans could be left behind.
If Congress failed to provide funding, "I think it'd be terrible, I think we'd see a lot of unnecessary loss of life if that were to happen," he said, but the Biden administration would try to find a way to provide vaccines to those at highest risk, he added.
M.O.Allen--AT